Related Experiment Videos
[Laboratory identification of blood hypercoagulability].
Srpski Arhiv Za Celokupno Lekarstvo
|June 23, 1999
Summary
Laboratory testing for thrombophilia has advanced, identifying causes for 40-60% of idiopathic thrombosis cases. New assays for genetic mutations and activation markers are improving diagnosis, though clinical adoption is gradual.
Area of Science:
- Hematology
- Clinical Pathology
- Molecular Diagnostics
Background:
- Laboratory investigation of thrombophilia has historically lagged behind bleeding disorders.
- Advances in understanding coagulation mechanisms have spurred interest in thrombophilia diagnostics.
- Established assays for activated protein C resistance, antithrombin, protein C, protein S deficiencies, and antiphospholipid antibodies are crucial for idiopathic thrombosis evaluation.
Discussion:
- Current assays can explain thrombosis in 40-60% of patients with idiopathic thrombosis.
- Fibrinogen and fibrinolysis abnormalities are less common causes but are being investigated.
- Emerging sophisticated assays target Factor V Leiden and prothrombin gene mutations for enhanced detection.
Key Insights:
- Widely available tests for common thrombophilic defects should be standard in idiopathic thrombosis workups.
- Newer genetic and activation marker assays promise to identify more thrombophilia cases.
- Despite diagnostic advancements, clinical laboratory acceptance of novel testing approaches remains slow.
Outlook:
- Continued development of sensitive laboratory tests for hypercoagulable states is expected.
- Integration of novel activation markers and genetic testing will refine thrombophilia diagnosis.
- Overcoming slow clinical adoption is key to realizing the full potential of advanced thrombophilia diagnostics.